Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Build Up Bone

Nancy Lane, MD, and Wei Yao, MD  |  Issue: June 2007  |  

However, we still have challenges ahead in the field of osteoporosis. We need more studies to further our understanding of how current bone-active agents improve bone strength, how long to treat patients with bone-active agents to improve bone strength, and how to better identify patients who will benefit from fracture prevention treatment. Although it is a chronic degenerative disease, osteoporosis can be diagnosed and treated, and—with optimal medical management—hopefully it can be cured.

References

  1. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007; E-pub ahead of print: DOI 10.1007/s00198-007-0343-y.
  2. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after five years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-2938.
  3. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20(1):141-151.
  4. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int. 2007;18(1):25-34.
  5. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753-761.
  6. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13):1207-1215.
  7. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005 Aug 11;353(6):555-565.
  8. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006;79(3):129-137.
  9. Lane NE, Sanchez S, Modin G, et al. Parathyroid hormone treatment can reverse steroid osteoporosis: results of a randomized clinical trial. J Clin Invest. 1998;102(8):1627–1633.
  10. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007; 13(2):156–163.
  11. Goldring SR, Goldring MB. Eating bone or adding it: the Wnt pathway decides. Nat Med. 2007;13(2):133-134.
  12. Jarrett SJ, Conaghan PG, Sloan VS, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum. 2006;54(5):1410-1414.
  13. Cohen SB, Dore RK, Lane N, et al. Denosumab treatment effects on structural damage, bone mineral density and bone turnover in rheumatoid arthritis: A randomized, double-blind, placebo-controlled clinical trial. NEJM, in press.

ADVERTISEMENT
SCROLL TO CONTINUE

Hospitalists as Test Subjects

Dr. Lane

Dr. Lane is endowed professor of medicine, vice chair for research in the department of medicine and rheumatology, and director at the Center for Healthy Aging at the University of California at Davis (UCD) in Sacramento. She received her undergraduate degree with highest honors at UCD and her medical degree at the University of California at San Francisco. Dr. Lane completed a residency in medicine at Mount Zion Hospital and Medical Center in San Francisco and a rheumatology clinical fellowship at the Palo Alto VA Hospital and Stanford University Medical Center (Calif).

Related Articles

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

    Reading Rheum

    Handpicked Reviews of Contemporary Literature

    Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

    Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…